Premium
P4‐238: Long‐term effects of galantamine on cognitive function in alzheimer's disease: A large‐scale international retrospective study
Author(s) -
Schaeuble Barbara,
Kavanagh Shane,
Van Baelen Bart
Publication year - 2011
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2011.05.2263
Subject(s) - galantamine , donepezil , placebo , cognitive decline , cognition , epidemiology , medicine , clinical trial , dementia , disease , psychology , psychiatry , alternative medicine , pathology
studied the mean changes of MMSE scores and CGI-C scores compared to baseline. Tolerability was measured by the incidence of adverse events (AE). Results: 10.627 patients with AD (mean age of 76 + 8 years, 59% female) and a mean MMSE score of 16 (+ 6) were analysed. Available information on co-morbidities demonstrated that the majority of patients were affected with at least one co-morbidity. After 6 months of treatment with memantine mean MMSE score improved significantly compared to baseline. Cognition was improved or stable in 79% of the patients. CGI-C scores improved or remained stable for 87% of patients. Tolerability of memantine was assessed as “very good” or “good” in 95% of all patients. Conclusions: This meta-analysis shows the clinical benefit of memantine in routine clinical practice based on more than 10.000 patients with Alzheimer’s disease. The results were consistent with the efficacy of memantine treatment seen in randomised controlled trials. In the majority of patients treated in routine clinical practice, cognitive and global abilities of patients were improved or stabilised during treatment with memantine. Tolerability of memantine was fine for almost all patients.